TREM2 AND AIRWAY DISEASE
TREM2 AND AIRWAY DISEASE
批准号:
9335933
负责人:
Michael J Holtzman
金额:
$44.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2020-07-31
关键词:
AcuteAddressApoptosisApoptoticAppearanceCell physiologyCell surfaceChronicChronic DiseaseDevelopmentDiseaseDouble-Stranded RNAEpithelial CellsEpitheliumHumanImmune responseIn VitroInfectionInflammatoryInflammatory ResponseInterleukin-13LocationLungMAP Kinase GeneMacrophage Colony-Stimulating FactorModelingMorbidity - disease rateMucosal Immune ResponsesMucosal ImmunityMucous MembraneMusMyelogenousNaturePathway interactionsPeptide HydrolasesPopulationProcessProductionProteinsPublic HealthRecruitment ActivityRegulationRoleSignal PathwaySignal TransductionSignal Transduction PathwaySiteStructure of parenchyma of lungSystemTREM2 geneTYROBP geneTechnologyTobacco smokingViralViral Respiratory Tract InfectionVirusVirus DiseasesVirus Replicationairway epitheliumbasecell typecommon treatmentcytokineeffective therapyexperiencefeedingimmune functionimprovedin vivokinase inhibitorknockout genemacrophagemortalitymouse modelpathogenpreventreceptorrespiratoryrespiratory virusresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The role of the mucosal immune response in protecting against acute infectious illness versus promoting
chronic inflammatory disease must be better defined to understand and treat these conditions. To address this
issue, we are pursuing evidence that lung macrophages efficiently infiltrate the airway mucosal epithelium and
adjacent parenchyma to control acute respiratory viral infection, but if unchecked could also contribute to
chronic airway disease after the infection is cleared. In support of this hypothesis, we have learned that lung
macrophages near the airway (in mucosal and adjacent parenchymal locations) express the myeloid receptor
TREM-2 as distinct cell-surface and soluble forms, and that each form can stimulate anti-apoptotic signaling in
macrophages to allow for macrophage survival. Thus, we showed that cell-surface TREM-2 is increased during
viral infection by the action of dsRNA and prevents macrophage apoptosis during acute viral illness, whereas
soluble TREM-2 (sTREM-2) is increased after clearance of infection by the actions of IL-13 and DAP12 and
prevents macrophage apoptosis to further increase IL-13 production and chronic post-viral disease. The
findings suggest that macrophages can be protective during the acute immune response but inflammatory
during the chronic immune response to respiratory viral infection based on new actions of the TREM-2
signaling pathway. Preliminary studies of humans show that respiratory viral infection and IL-13 can also
increase cell-surface and soluble TREM-2 levels in human macrophages.
We now aim to further define the role of macrophage TREM-2 in acute and chronic mucosal immune
responses to respiratory viral infection. Critical questions include: how cell-surface and soluble TREM-2 levels
are regulated in lung macrophages, and how cell-surface and soluble forms of TREM-2 control anti-apoptotic
pathways, especially in macrophage populations near the airway epithelium. We propose that TREM-2
(particularly as the cell-surface form) is an integral component of mucosal immunity whereas an exaggerated
level of TREM-2 (particularly as the soluble form) provides a feed-forward mechanism to drive an excessive
type 2 immune response. Thus, the cell-surface form of TREM-2 could protect against acute viral infection but
the soluble form could promote chronic post-viral disease. We will especially compare the regulation and
function of cell-surface to soluble TREM-2 to develop the hypothesis that down-regulating soluble TREM-2
level might even enhance cell-surface TREM-2 level and thereby improve immune function at mucosal
barriers. Based on our preliminary studies, we next aim to: (1) define how TREM-2 is expressed, focusing on
the appearance of TREM-2 at the cell surface and the cleavage of cell-surface TREM-2 to soluble TREM-2 in
macrophages; and (2) define how cell-surface and soluble TREM-2 signal to inhibit apoptosis in macrophages,
focusing on any differences between the two forms of TREM-2 in activating downstream signal transduction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining and Controlling Airway Disease
-
批准号:10352375
-
项目类别:
-
资助金额:$94.5万
-
财政年份:2019
-
负责人:Michael J Holtzman
-
依托单位:
Defining and Controlling Airway Disease
-
批准号:10579266
-
项目类别:
-
资助金额:$94.5万
-
财政年份:2019
-
负责人:Michael J Holtzman
-
依托单位:
Defining and Controlling Airway Disease
-
批准号:9889988
-
项目类别:
-
资助金额:$94.4万
-
财政年份:2019
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:9223736
-
项目类别:
-
资助金额:$46.48万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:8790768
-
项目类别:
-
资助金额:$46.92万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
Preclinical Development of an Anti-Mucus Drug
-
批准号:8748733
-
项目类别:
-
资助金额:$151.34万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
INTERFERON SIGNAL ENHANCERS AS ANTIVIRAL THERAPEUTICS
-
批准号:8697863
-
项目类别:
-
资助金额:$44.09万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:8632665
-
项目类别:
-
资助金额:$48.19万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
Preclinical Development of an Anti-Mucus Drug
-
批准号:9317525
-
项目类别:
-
资助金额:$150.42万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:8996714
-
项目类别:
-
资助金额:$47.06万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
Target Validation and Assay Development for Anti-Mucus Therapy
-
批准号:8073309
-
项目类别:
-
资助金额:$45.6万
-
财政年份:2011
-
负责人:Michael J Holtzman
-
依托单位:
Stat 1 modification for antiviral defense
-
批准号:8234937
-
项目类别:
-
资助金额:$38.33万
-
财政年份:2011
-
负责人:Michael J Holtzman
-
依托单位:
Target Validation and Assay Development for Anti-Mucus Therapy
-
批准号:8262679
-
项目类别:
-
资助金额:$45.6万
-
财政年份:2011
-
负责人:Michael J Holtzman
-
依托单位:
New Immune Pathways for Epithelial Remodeling
-
批准号:8147488
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2010
-
负责人:Michael J Holtzman
-
依托单位:
Innate and Adaptive Immune Signaling in Asthma
-
批准号:7927711
-
项目类别:
-
资助金额:$197.63万
-
财政年份:2009
-
负责人:Michael J Holtzman
-
依托单位:
Innate and Adaptive Immune Signaling in Asthma
-
批准号:7918436
-
项目类别:
-
资助金额:$49.26万
-
财政年份:2009
-
负责人:Michael J Holtzman
-
依托单位:
Stat 1 modification for antiviral defense
-
批准号:7672133
-
项目类别:
-
资助金额:$38.2万
-
财政年份:2009
-
负责人:Michael J Holtzman
-
依托单位:
Administrative
-
批准号:7392544
-
项目类别:
-
资助金额:$19.16万
-
财政年份:2007
-
负责人:Michael J Holtzman
-
依托单位:
Alveolar and Airway Mechanisms for COPD
-
批准号:7749011
-
项目类别:
-
资助金额:$280.3万
-
财政年份:2007
-
负责人:Michael J Holtzman
-
依托单位:
Alveolar and Airway Mechanisms for COPD
-
批准号:8004055
-
项目类别:
-
资助金额:$280.33万
-
财政年份:2007
-
负责人:Michael J Holtzman
-
依托单位:
海外基金